X4 Pharmaceuticals (XFOR) Current Assets (2017 - 2025)

X4 Pharmaceuticals' Current Assets history runs 9 years deep, the most recent figure standing at $261.6 million for Q4 2025.

• Quarterly Current Assets rose 133.19% year-over-year to $261.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $261.6 million (up 133.19% YoY) and the FY2025 annual result came in at $261.6 million, up 133.19% from the prior year.
• Current Assets was $261.6 million for Q4 2025 at X4 Pharmaceuticals, up from $132.8 million in the prior quarter.
• Across five years, Current Assets topped out at $261.6 million in Q4 2025 and bottomed at $52.6 million in Q2 2022.
• A 5-year average of $116.2 million and a median of $106.8 million in 2021 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets surged 180.78% — and 2025, when it tumbled 58.42%.
• X4 Pharmaceuticals' Current Assets stood at $87.9 million in 2021, then jumped by 46.43% to $128.7 million in 2022, then retreated by 5.13% to $122.1 million in 2023, then fell by 8.11% to $112.2 million in 2024, then surged by 133.19% to $261.6 million in 2025.
• Business Quant data shows XFOR's Current Assets at $261.6 million in Q4 2025, $132.8 million in Q3 2025, and $72.9 million in Q2 2025.